Vmbook Online ordering

Icons

I could not find a company listed on a US stock exchange with the symbol "CHECK-ALL." However, I did find a company named "Check-Cap Ltd" that is listed on the NASDAQ stock exchange under the symbol "CHEK."

Check-Cap is an Israeli medical diagnostics company that focuses on the development of capsule-based imaging and diagnostic solutions. The company's primary product is the C-Scan, a miniature capsule that uses X-ray and wireless communication technology to capture images of the gastrointestinal tract.

Check-Cap was founded in 2005 and became a public company in 2018 through an IPO on the NASDAQ stock exchange. Since then, the company's stock has experienced significant volatility, reflecting the risks and uncertainties associated with early-stage medical technology companies.

In terms of financial performance, Check-Cap has yet to generate significant revenues or profits. In 2020, the company reported a net loss of $11.4 million, compared to a net loss of $10.2 million in 2019. The company's cash balance at the end of 2020 was $11.8 million, which the company expects will be sufficient to fund its operations through the first half of 2022.

Despite the lack of profitability, Check-Cap has made significant progress in its product development initiatives. In November 2021, the company announced that it had received approval from the US Food and Drug Administration (FDA) to conduct a pivotal study of the C-Scan system in the United States. This represents a significant milestone for the company and could potentially lead to regulatory approval and commercialization of the C-Scan system in the United States.

In summary, Check-Cap is an early-stage medical technology company focused on the development of capsule-based diagnostic solutions. While the company has yet to generate significant revenues or profits, it has made progress in product development and regulatory approvals, which could potentially lead to commercial success in the future. As with any investment, potential investors should carefully evaluate the risks and uncertainties associated with early-stage medical technology companies and consult with a qualified financial advisor before making any investment decisions.